SCHEMBL149707

SCHEMBL149707

Cn1c(N)nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.61
NOS2 P35228 1/20 0.61
POLB P06746 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
HTT P42858 1/20 0.58
CXCR4 P61073 1/20 0.58
KDM4E B2RXH2 3/20 0.58
NPC1 O15118 2/20 0.58
GAA P10253 2/20 0.58
RAB9A P51151 2/20 0.58
ALDH1A1 P00352 1/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
ALOX15 P16050 1/20 0.58
HSD17B10 Q99714 1/20 0.58
ATM Q13315 1/20 0.57
TLR8 Q9NR97 3/20 0.56
PRMT5 O14744 1/20 0.52
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30621933 1.00 SMN1; SMN2 (0.61) SMN1; SMN2NOS2POLBCYP1A2CYP2D6
Iodide SCHEMBL336130 0.98 SMN1; SMN2 (0.59) SMN1; SMN2NOS2POLBCYP1A2CYP2D6
Iodide SCHEMBL336131 0.98 SMN1; SMN2 (0.59) SMN1; SMN2NOS2POLBCYP1A2CYP2D6
SCHEMBL28115610 0.80 RAB9A (0.48) SMN1; SMN2POLBHTTKDM4ENPC1
SCHEMBL27588340 0.80 POLB (0.49) SMN1; SMN2NOS2POLBCYP1A2CYP2D6
SCHEMBL21555494 0.78 KDM4E (0.65) SMN1; SMN2NOS2POLBCYP1A2CYP2D6
SCHEMBL1171430 0.77 MEN1 (0.69) SMN1; SMN2POLBHTTKDM4ENPC1
SCHEMBL6199065 0.77 CXCR4 (0.85) NOS2POLBCYP1A2CYP2D6HTT
SCHEMBL16065946 0.76 SMN1; SMN2 (0.53) SMN1; SMN2NOS2POLBHTTKDM4E
SCHEMBL15540772 0.76 PIK3CA (0.49) POLBCYP1A2CYP2D6KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 CN claimed
CN-118105738-A Preparation method of novel anionic demulsifier for cutting fluid wastewater treatment 苏州顿莱环保科技有限公司 2024-05-31 CN claimed
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES UCB Biopharma SRL (BE) 2024-03-21 US claimed
CN-116157398-A 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy 意大发马克股份公司 2023-05-23 CN claimed
WO-2021130257-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES UCB Biopharma SRL (BE) 2021-07-01 WO claimed
US-20130139887-A1 SCALABLE PRODUCTION OF DYE-SENSITIZED SOLAR CELLS USING INKJET PRINTING BRITE HELLAS AE (GR) 2013-06-06 US claimed
US-8173638-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US claimed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US claimed
US-20110203644-A1 QUASI-SOLID-STATE PHOTOELECTROCHEMICAL SOLAR CELL FORMED USING INKJET PRINTING AND NANOCOMPOSITE ORGANIC-INORGANIC MATERIAL BRITE HELLAS AE (GR) 2011-08-25 US claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
WO-2008064054-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-29 WO claimed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
CN-1558898-A Antiviral agent ��Ұ����ҩ��ʽ���� 2004-12-29 CN claimed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES FCER2, FCGR2A, FCGR1A SMN1; SMN2 4793/4885NOS2 174/4885POLB 4743/4885
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 SMN1; SMN2 4245/4885NOS2 2142/4885POLB 3230/4885
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 SMN1; SMN2 3446/4885NOS2 294/4885POLB 3740/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 SMN1; SMN2 4601/4885NOS2 2537/4885POLB 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.